Phase 1 Clinical Pharmacology Study of JTZ-951

Phase 1 Clinical Study of JTZ-951 - Clinical Pharmacology study -

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221924

Enrollment

Registered

2012-09-24

Start date

2012-09-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Interventions

investigational material(s) Generic name etc : JTZ-951 INN of investigational material : Enarodustat Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and Administ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients undergoing hemodialysis consistently 3 times weekly -Dry weight between 35kg and 70kg

Exclusion criteria

Exclusion criteria: -Systolic blood pressure of 180 mmHg or more and diastolic blood pressure of 110 mmHg or more -Patients with congestive heart failure -Patients with malignancy

Design outcomes

Primary

Measure	Time frame
safety pharmacokinetics -Plasma concentrations of JTZ-951 -Subjective symptoms, objective findings, vital signs, 12-lead ECG, laboratory tests	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026